Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease
Public ClinicalTrials.gov record NCT06079190. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Parallel Group, Randomized, Double- Blind, Placebo-Controlled, 3-Arm, Multicenter Treatment Study to Evaluate the Efficacy and Safety of GSK4527226 [AL101] Intravenous Infusion Compared With Placebo in Patients With Early Alzheimer's Disease
Study identification
- NCT ID
- NCT06079190
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- GlaxoSmithKline
- Industry
- Enrollment
- 367 participants
Conditions and interventions
Conditions
Interventions
- GSK4527226 Drug
- Placebo Other
Drug · Other
Eligibility (public fields only)
- Age range
- 50 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 19, 2023
- Primary completion
- Sep 29, 2026
- Completion
- Nov 22, 2026
- Last update posted
- Nov 13, 2025
2023 – 2026
United States locations
- U.S. sites
- 21
- U.S. states
- 13
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | San Diego | California | 92103 | — |
| GSK Investigational Site | Lake Mary | Florida | 32720 | — |
| GSK Investigational Site | Lake Worth | Florida | 33462 | — |
| GSK Investigational Site | Maitland | Florida | 32752 | — |
| GSK Investigational Site | Miami | Florida | 33176 | — |
| GSK Investigational Site | Orlando | Florida | 32803 | — |
| GSK Investigational Site | Orlando | Florida | 32804 | — |
| GSK Investigational Site | Stuart | Florida | 34997 | — |
| GSK Investigational Site | The Villages | Florida | 32159 | — |
| GSK Investigational Site | The Villages | Florida | 32162 | — |
| GSK Investigational Site | Decatur | Georgia | 30030 | — |
| GSK Investigational Site | Elk Grove Village | Illinois | 60007 | — |
| GSK Investigational Site | Chesterfield | Missouri | 63005 | — |
| GSK Investigational Site | Toms River | New Jersey | 08755 | — |
| GSK Investigational Site | Staten Island | New York | 10314 | — |
| GSK Investigational Site | Matthews | North Carolina | 28105 | — |
| GSK Investigational Site | North Canton | Ohio | 44720 | — |
| GSK Investigational Site | Oklahoma City | Oklahoma | 73112 | — |
| GSK Investigational Site | Portland | Oregon | 07210 | — |
| GSK Investigational Site | Houston | Texas | 77030 | — |
| GSK Investigational Site | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 76 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06079190, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 13, 2025 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06079190 live on ClinicalTrials.gov.